Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.
Tell us about a missing company
Novo Nordisk A/S clinical trials
The registry lists 1,444 studies whose lead sponsor is Novo Nordisk A/S or one of 6 companies grouped under it. 108 are recruiting or about to start. Per ClinicalTrials.gov, last updated Oct 26, 2026.
Keep track of what changes. Save the Novo Nordisk A/S studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesStatus
Registry sponsor names on this page
Each name exactly as ClinicalTrials.gov lists it, and how it relates to Novo Nordisk A/S.
- Novo Nordisk A/S1,401 studiesSame company
Something wrong?
- Dicerna Pharmaceuticals, Inc., a Novo Nordisk company18 studies →Acquired — became part of Novo Nordisk A/S, Dec 28, 2021 · source ↗
Something wrong?
- Forma Therapeutics, Inc.10 studies →Acquired — became part of Novo Nordisk A/S, Oct 14, 2022 · source ↗
Something wrong?
- Akero Therapeutics, Inc6 studies →Acquired — became part of Novo Nordisk A/S, Dec 9, 2025 · source ↗
Something wrong?
- Inversago Pharma Inc.4 studies →Acquired — became part of Novo Nordisk A/S, Sep 11, 2023 · source ↗
Something wrong?
- Cardior Pharmaceuticals GmbH3 studies →Acquired — became part of Novo Nordisk A/S, May 2, 2024 · source ↗
Something wrong?
- Emisphere Technologies, Inc.2 studies →Acquired — became part of Novo Nordisk A/S, Dec 8, 2020 · source ↗
Something wrong?
Focus areas
Conditions Novo Nordisk A/S leads ten or more studies in, by study count. A broader condition is left out when almost all its studies are already in a narrower one listed here.
Diabetes Mellitus, Type 2633Diabetes Mellitus, Type 1226Obesity175Overweight121Hemostatic Disorders104Hemophilia A95Hemophilia B54Nutrition Disorders37Hemorrhage29Dwarfism, Pituitary27Renal Insufficiency, Chronic27Genetic Diseases, Inborn22Non-alcoholic Fatty Liver Disease18Kidney Diseases16Heart Failure14Arthritis, Rheumatoid13Cardiovascular Diseases13Fatty Liver13Turner Syndrome12Anemia, Sickle Cell11Atherosclerosis10
Studies
Recruiting first, then most recently updated. Showing 50 of 1,444. Browse all 1,444 →
- A Study to See How Safe a New Medicine (NNC0642-1895) is in Healthy PeopleRecruitingNCT07829406Phase 1
- A Research Study to Check the Safety of NNC9836-0001 When Given to Healthy Participants and Participants With Type 2 DiabetesNot yet recruitingNCT07896109Phase 1
- CLEOPATTRA: A Research Study to Look at the Effects of Treatment With a Medicine Called Coramitug (NNC6019-0001) in People With Heart Failure Due to Transthyretin Amyloid (ATTR) AmyloidosisRecruitingNCT07207811Phase 3
- A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in Children and Adolescents With Type 2 DiabetesRecruitingNCT07282613Phase 3
- Evaluation of the Tolerability of Cagrilintide in Participants Not Tolerating GLP-1-RA Therapies Due to Gastrointestinal Adverse EventsRecruitingNCT07607587Phase 1
- Semaglutide Health Outcomes and Patient Adherence in AustraliaNot yet recruitingNCT07881770
- A Research Study Investigating How Adults With Overweight or Obesity, With or Without Type 2 Diabetes, Tolerate Switching to a New Treatment (Zenagamtide) From Their Current Semaglutide MedicationRecruitingNCT07855133Phase 1
- A Research Study Investigating How Adults With Overweight or Obesity, With or Without Type 2 Diabetes, Tolerate Switching to a New Treatment (Zenagamtide) From Their Current Tirzepatide MedicationRecruitingNCT07868354Phase 1
- A Study Evaluating Efruxifermin in Subjects With Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and FibrosisRecruitingNCT06215716Phase 3
Sponsor listed in the registry: Akero Therapeutics, Inc · First submitted before Akero Therapeutics, Inc became part of Novo Nordisk A/S
- A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASHRecruitingNCT06528314Phase 3
Sponsor listed in the registry: Akero Therapeutics, Inc · First submitted before Akero Therapeutics, Inc became part of Novo Nordisk A/S
- French Registry of Children Treated With Norditropin® for Short Stature Associated With Noonan SyndromeEnrolling by invitationNCT05308927
- Adverse Event Data Collection From External Registries on Nonacog Beta PegolEnrolling by invitationNCT03690336
- Adverse Event Data Collection From the EUHASS Registry on Turoctocog Alfa PegolEnrolling by invitationNCT04682145
- Influence of Adherence to Growth Hormone Therapy (GHT) With Norditropin® on Near Final Height in Patients With Growth Hormone Deficiency (GHD) and Born Small for Gestational Age (SGA)Enrolling by invitationNCT03972345
- AMAZE 4: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Obstructive Sleep Apnoea Treated With Positive Airway Pressure Lose Weight and Improve Sleep ApnoeaRecruitingNCT07571109Phase 3
- A Research Study Comparing How Well Different Doses of the Medicine UBT251 Lower Blood Sugar in People With Type 2 DiabetesRecruitingNCT07668388Phase 2
- A Research Study Looking at the Effect of Timing of Meal After Dosing and Water Volume at Dosing on How the Medicine Zenagamtide is Taken up by the Body of Participants With Overweight or ObesityRecruitingNCT07815067Phase 1
- Patient Preferences in Treatment of Haemophilia A With and Without Inhibitors: a Discrete Choice Experiment in GermanyEnrolling by invitationNCT07653139
- A Research Study to Look at How Well Zenagamtide Works Compared to Placebo in People With Established Atherosclerotic Cardiovascular Disease and Either Overweight or ObesityNot yet recruitingNCT07861100Phase 3
- A Research Study Comparing Different Doses of CDR132L With Placebo on the Structure and Function of the Heart in People With Heart Failure With Preserved Ejection Fraction and Left Ventricular HypertrophyRecruitingNCT06979362Phase 2
- A Research Study to See How NNC0487-0111 Affects the Body's Energy Use After a Weight Loss in Adults Living With Overweight or Obesity, Compared to a Low-calorie Diet or PlaceboRecruitingNCT07757087Phase 1
- WEgovy Real World Assessment of Weight Loss in KoreaEnrolling by invitationNCT07280221
- AMAZE 2: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Type 2 Diabetes Lose WeightRecruitingNCT07533175Phase 3
- A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body WeightRecruitingNCT07253285Phase 3
- A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose WeightRecruitingNCT07564414Phase 3
- A Study to See How Safe a New Medicine (NNC0705-0002) is in Healthy PeopleRecruitingNCT07797855Phase 1
- Research Study on How People With Type 2 Diabetes Tolerate Switching From Semaglutide to CagrisemaRecruitingNCT07817251Phase 3
- A Research Study Looking Into How a High Dose of s.c. Semaglutide Works With Emptying of the Stomach in People With Excess Body WeightNot yet recruitingNCT07845578Phase 1
- A Research Study Investigating How Well the Medicine Zenagamtide Helps People With Excess Body Weight Lose Weight Compared to SemaglutideRecruitingNCT07668414Phase 3
- AMAZE 9: A Research Study Investigating How Well Zenagamtide Tablets Help People With Excess Body Weight Lose WeightRecruitingNCT07720271Phase 3
- A Research Study to See How Safe is Eptacog Alfa When Used to Stop Heavy Bleeding in Women After Giving Birth in IndiaRecruitingNCT07157423Phase 4
- AMAZE 1: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight Lose WeightRecruitingNCT07339423Phase 3
- A Research Study Investigating Denecimig (Mim8) in Adults With Acquired Haemophilia ANot yet recruitingNCT07830732Phase 3
- A Study to Evaluate the Pharmacokinetics and Safety of Etavopivat in Pediatric Patients With Sickle Cell DiseaseRecruitingNCT06198712Phase 2
Sponsor listed in the registry: Forma Therapeutics, Inc. · First submitted after Forma Therapeutics, Inc. became part of Novo Nordisk A/S
- A Research Study Looking at Long-term Treatment With Etavopivat in People With Sickle Cell Disease or ThalassaemiaRecruitingNCT06609226Phase 3
- Regulatory Post Marketing Surveillance (rPMS) Study of Rybelsus (Oral Semaglutide) to Evaluate Safety and Effectiveness in Patients With Type 2 Diabetes Mellitus in Routine Clinical Practice in KoreaNot yet recruitingNCT05714683
- A Research Study Looking at How Different Doses of Study Medicine (Inno8) Work in the Body of People With Haemophilia ARecruitingNCT07220564Phase 1
- A Research Study to Examine Blood Sugar Control, Treatment Satisfaction and Adherence in People With Type 2 Diabetes After Switching From Daily Basal Insulin to Once-weekly Insulin IcodecEnrolling by invitationNCT07632404
- A Study to Evaluate How Well Etavopivat Works in People With Sickle Cell DiseaseRecruitingNCT06612268Phase 3
- Cities for Better Health Childhood Obesity Prevention InitiativeEnrolling by invitationNCT06855563Not applicable
- AMAZE 10: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People in Japan With Excess Body Weight Lose WeightRecruitingNCT07822061Phase 3
- Research Study to Examine Blood Sugar Control, Treatment Satisfaction and Adherence in People With Type 2 Diabetes After Switching From Daily Basal Insulin to Once-weekly Insulin IcodecEnrolling by invitationNCT07658417
- Study to Assess Tolerability of Injecting Larger Volumes (2-5 mL) Subcutaneously at Different Rates: Participant Experience and AcceptanceRecruitingNCT07769489Phase 1
- A Research Study Comparing How Well Different Doses of the Medicine NNC0662-0419 Lower Blood Sugar in People With Type 2 DiabetesRecruitingNCT07415954Phase 2
- AMAZE 3: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Obstructive Sleep Apnoea Not Treated With Positive Airway Pressure Lose Weight and Improve Sleep ApnoeaRecruitingNCT07571005Phase 3
- A Phase 2 Open-label Study to Evaluate the Activity of Etavopivat on Transcranial Doppler Velocities in Pediatric Patients With Sickle Cell Disease Who Are at Increased Risk for Primary StrokeRecruitingNCT05953584Phase 2
Sponsor listed in the registry: Forma Therapeutics, Inc. · First submitted after Forma Therapeutics, Inc. became part of Novo Nordisk A/S
- Compassionate Use of Concizumab if You Have HaemophiliaAvailableNCT04921956
- The Role of the Amylin Analogue Cagrilintide in Bone MetabolismRecruitingNCT07010432Phase 1
- A Research Study Investigating How a New Medicine NNC0113-5840 Works in People With Overweight or ObesityRecruitingNCT07566390Phase 1
- Research Study on How Well Oral Semaglutide Works for Weight Loss in Adults With Excess Body WeightRecruitingNCT07770841Phase 3